SCHEMBL4134784

SCHEMBL4134784

O=C(c1ccc(N2CCC3(CC2)CCN(C2CCC2)CC3)cc1)N1CCOCC1

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 7/20 0.60
L3MBTL1 Q9Y468 6/20 0.60
MBTD1 Q05BQ5 2/20 0.60
TP53BP1 Q12888 2/20 0.60
L3MBTL4 Q8NA19 2/20 0.60
HRH3 Q9Y5N1 8/20 0.57
HPGD P15428 2/20 0.51
CYP3A4 P08684 1/20 0.51
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
MAPT P10636 1/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HSD11B1 P28845 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4147049 0.91 L3MBTL3 (0.67) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL4130681 0.90 L3MBTL3 (0.66) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL4139958 0.90 L3MBTL3 (0.66) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL4136891 0.87 L3MBTL3 (0.62) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL4282496 0.87 L3MBTL3 (0.58) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL4134873 0.85 ALDH1A1 (0.65) L3MBTL3L3MBTL1HRH3HPGDKDM4E
SCHEMBL4284110 0.84 L3MBTL3 (0.52) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL14529143 0.84 L3MBTL3 (0.84) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL14528665 0.83 L3MBTL3 (0.78) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL1169820 0.83 L3MBTL3 (0.66) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 EP claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US claimed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 L3MBTL3 2655/4885L3MBTL1 2620/4885MBTD1 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.